tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Blepharitis D001762 4 associated lipids
Diabetes Complications D048909 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Hallucinations D006212 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Prurigo D011536 4 associated lipids
Sclerosis D012598 5 associated lipids
Mastocytosis D008415 5 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Tinea D014005 5 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Liver Failure D017093 5 associated lipids
Osteomalacia D010018 5 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Trypanosomiasis D014352 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Hematoma D006406 5 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Respiration Disorders D012120 5 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Mouth Diseases D009059 5 associated lipids
Postoperative Complications D011183 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Angioedema D000799 6 associated lipids
Gynecomastia D006177 6 associated lipids
Thrombophlebitis D013924 6 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Heart Injuries D006335 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Coronary Stenosis D023921 6 associated lipids
Liver Abscess D008100 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Pericarditis D010493 6 associated lipids
Blindness D001766 6 associated lipids
Alopecia Areata D000506 6 associated lipids
Gliosis D005911 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Infection D007239 6 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Pancytopenia D010198 6 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Graves Disease D006111 6 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Facial Dermatoses D005148 7 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Tachycardia D013610 7 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Folliculitis D005499 7 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Dyslipidemias D050171 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Chronic Disease D002908 7 associated lipids
Metaplasia D008679 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Behcet Syndrome D001528 7 associated lipids
Hepatitis C D006526 7 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Dementia, Vascular D015140 7 associated lipids
Renal Insufficiency D051437 8 associated lipids
Fistula D005402 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Opportunistic Infections D009894 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Lupus Nephritis D008181 8 associated lipids
Thyroid Diseases D013959 8 associated lipids
Sinusitis D012852 9 associated lipids
Cicatrix D002921 9 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Leukocytosis D007964 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Urination Disorders D014555 9 associated lipids
Hypertension, Renal D006977 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Long QT Syndrome D008133 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Prescott TA et al. A yeast chemical genetics approach identifies the compound 3,4,5-trimethoxybenzyl isothiocyanate as a calcineurin inhibitor. 2014 FEBS Lett. pmid:24374339
Perlman RL and Rao PS Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment. 2014 Drugs Aging pmid:24399579
Tanaka K et al. Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases. 2014 J. Hum. Genet. pmid:24352002
Erdinest N and Solomon A Topical immunomodulators in the management of allergic eye diseases. 2014 Curr Opin Allergy Clin Immunol pmid:25054831
Mo D et al. In vitro interactions of calcineurin inhibitors with conventional antifungal agents against the yeast form of Penicillium marneffei. 2014 Mycopathologia pmid:25052248
Gołębiewska J et al. Tako-tsubo cardiomyopathy on the first day after renal transplantation - case report and literature review. 2014 Transplant. Proc. pmid:25380951
Ünlüsoy Aksu A et al. Immune thrombocytopenic purpura in a liver transplant patient. 2014 Exp Clin Transplant pmid:24635822
Bakkour W et al. Successful use of dapsone for the management of circinate balanitis. 2014 Clin. Exp. Dermatol. pmid:24635073
Kapoor K et al. Lip hypertrophy due to cyclosporine therapy. 2014 Clin. Exp. Nephrol. pmid:23615783
Alloway RR et al. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. 2014 Liver Transpl. pmid:24493215
Hartmann A et al. Treatment of generalised vitiligo with tacrolimus 0.1% ointment vs. UVB intense pulsed light phototherapy: a pilot study. 2014 Acta Derm. Venereol. pmid:24473666
Xu H et al. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 2014 Am. J. Transplant. pmid:24472192
Tsuchimoto A et al. Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. 2014 PLoS ONE pmid:25329716
Lankarani KB et al. Response to: Comment on: New-onset diabetes and impaired fasting glucose after liver transplant: risk analysis and the impact of tacrolimus dose. 2014 Exp Clin Transplant pmid:24471728
Qi H et al. The antiaging activity and cerebral protection of rapamycin at micro-doses. 2014 CNS Neurosci Ther pmid:25327787
Kuypers DR et al. Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients. 2014 Pharmacogenet. Genomics pmid:25322286
Balato A et al. Tacrolimus does not alter the production of several cytokines and antimicrobial peptide in Malassezia furfur-infected-keratinocytes. 2014 Mycoses pmid:24512536
Li CJ et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. 2014 PLoS ONE pmid:24465960
Silva-Cunha A et al. Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus. 2014 J Ocul Pharmacol Ther pmid:24199740
Diémé B et al. Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. 2014 Transplantation pmid:24598938
Grillo E et al. Necrobiosis lipoidica. 2014 Aust Fam Physician pmid:24600675
Kimura Y et al. Evaluation of the Multi-ImmunoTox Assay composed of 3 human cytokine reporter cells by examining immunological effects of drugs. 2014 Toxicol In Vitro pmid:24603311
Daher Abdi Z et al. Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. 2014 Clin. Pharmacol. Ther. pmid:24968086
Sapir-Pichhadze R et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. 2014 Kidney Int. pmid:24336032
Danby SG et al. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. 2014 Br. J. Dermatol. pmid:24328907
Kato H et al. Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome. 2014 Bone Marrow Transplant. pmid:24317130
Budde K et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. 2014 Am. J. Transplant. pmid:25278376
Urbanowicz T et al. Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. 2014 Ann. Transplant. pmid:25274118
Stifft F et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. 2014 Transplantation pmid:24686426
Funaro D et al. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. 2014 J. Am. Acad. Dermatol. pmid:24704090
Demmers MW et al. Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. 2014 Transplantation pmid:24704664
Størset E et al. Importance of hematocrit for a tacrolimus target concentration strategy. 2014 Eur. J. Clin. Pharmacol. pmid:24071959
Peloso LJ et al. The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. 2014 Transplantation pmid:25221905
Posadas Salas MA and Srinivas TR Update on the clinical utility of once-daily tacrolimus in the management of transplantation. 2014 Drug Des Devel Ther pmid:25210441
Taber DJ et al. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients. 2014 Am. J. Nephrol. pmid:24969370
Keniya MV et al. Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5. 2014 Mol. Pharm. pmid:25115303
Sun Z et al. Co-administration of Wuzhi capsules and tacrolimus in patients with idiopathic membranous nephropathy: clinical efficacy and pharmacoeconomics. 2014 Int Urol Nephrol pmid:25145781
Dannhorn E et al. De novo use of generic tacrolimus in liver transplantation - a single center experience with one-yr follow-up. 2014 Clin Transplant pmid:25142496
Chatterjea A et al. Suppression of the immune system as a critical step for bone formation from allogeneic osteoprogenitors implanted in rats. 2014 J. Cell. Mol. Med. pmid:24237965
Feliu J et al. Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies. 2014 Br. J. Haematol. pmid:24962133
Størset E et al. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. 2014 Br J Clin Pharmacol pmid:25279405
Ko SF et al. Therapeutic potential of tacrolimus on acute myocardial infarction in minipigs: analysis with serial cardiac magnetic resonance and changes at histological and protein levels. 2014 Biomed Res Int pmid:25114905
Grossman J et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. 2014 Biol. Blood Marrow Transplant. pmid:25111582
Sethna CB and Gipson DS Treatment of FSGS in Children. 2014 Adv Chronic Kidney Dis pmid:24602468
Bercaw-Pratt JL et al. Clinical recommendation: pediatric lichen sclerosus. 2014 J Pediatr Adolesc Gynecol pmid:24602304
Kaieda S et al. Successful treatment of rectal ulcers in a patient with systemic lupus erythematosus using corticosteroids and tacrolimus. 2014 Mod Rheumatol pmid:24593214
Kraus TS et al. Angioimmunoblastic T cell lymphoma: an unusual presentation of posttransplant lymphoproliferative disorder in a pediatric patient. 2014 Acta Haematol. pmid:24157860
Little JA et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. 2014 J. Rheumatol. pmid:24085549
Hostettler KE et al. Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation. 2014 Eur. Respir. J. pmid:23645405
Oh CK et al. Safety and efficacy of conversion from twice-daily tacrolimus to once-daily tacrolimus one month after transplantation: randomized controlled trial in adult renal transplantation. 2014 Yonsei Med. J. pmid:25048494
Matin M et al. The effectiveness of excimer laser on vitiligo treatment in comparison with a combination therapy of Excimer laser and tacrolimus in an Iranian population. 2014 J Cosmet Laser Ther pmid:25046236
de la Fuente V et al. Calcineurin phosphatase as a negative regulator of fear memory in hippocampus: control on nuclear factor-κB signaling in consolidation and reconsolidation. 2014 Hippocampus pmid:25043904
Kluk J et al. Follicular mucinosis treated with topical 0.1% tacrolimus ointment. 2014 Clin. Exp. Dermatol. pmid:24252117
Ohe M et al. Successful treatment with tacrolimus of refractory adult-onset Still's disease. 2014 Korean J. Intern. Med. pmid:24648814
Friedrich RB et al. Nanoencapsulation of tacrolimus in lipid-core nanocapsules showed similar immunosuppressive activity after oral and intraperitoneal administrations. 2014 J Biomed Nanotechnol pmid:25016659
Rostaing L et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. 2014 Ann. Transplant. pmid:25017487
Qi H et al. Enhancement of ascomycin production in Streptomyces hygroscopicus var. ascomyceticus by combining resin HP20 addition and metabolic profiling analysis. 2014 J. Ind. Microbiol. Biotechnol. pmid:24965502
Jannot M et al. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge. 2014 Ann. Transplant. pmid:24999809
Wannhoff A et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. 2014 Transplantation pmid:25022236
Toniutto P et al. Biliary strictures after liver transplantation: role of interleukin 28B genotypes in cyclosporine treated. 2014 Int J Surg pmid:25219480
Boonyapredee M et al. Increased BK viremia and progression to BK-virus nephropathy following high-dose intravenous immunoglobulin for acute cellular rejection. 2014 Mil Med pmid:24902140
Langone A et al. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation. 2014 Clin Transplant pmid:24893821
Nafar M et al. Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients. 2014 Iran J Kidney Dis pmid:24878947
van Gelder T Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. 2014 Kidney Int. pmid:24875549
Tümgör G et al. A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. 2014 Turk J Gastroenterol pmid:25599790
Stifft F et al. Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers. 2014 Br J Clin Pharmacol pmid:24809233
Korbel L et al. Clinically relevant pharmacogenomic testing in pediatric practice. 2014 Clin Pediatr (Phila) pmid:24803633
Kallash M and Aviles D Efficacy of tacrolimus in the treatment of children with focal segmental glomerulosclerosis. 2014 World J Pediatr pmid:24801235
Maeda H et al. Disappearance of GFP-positive hepatocytes transplanted into the liver of syngeneic wild-type rats pretreated with retrorsine. 2014 PLoS ONE pmid:24796859
Du W et al. Improved FK506 production by the precursors and product-tolerant mutant of Streptomyces tsukubaensis based on genome shuffling and dynamic fed-batch strategies. 2014 J. Ind. Microbiol. Biotechnol. pmid:24788378
Nkongolo S et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. 2014 J. Hepatol. pmid:24295872
Levy G et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 2014 Am. J. Transplant. pmid:24456049
Parashos SA et al. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 2014 JAMA Neurol pmid:24711047
Gillard P et al. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. 2014 Transplantation pmid:24770614
Pandey S et al. Metabotropic glutamate receptor 1 recycles to the cell surface in protein phosphatase 2A-dependent manner in non-neuronal and neuronal cell lines. 2014 J. Neurochem. pmid:25113668
Supe-Markovina K et al. Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience. 2014 Pediatr Transplant pmid:24712738
Chung BH et al. Decrease of immature B cell and interleukin-10 during early-post-transplant period in renal transplant recipients under tacrolimus based immunosuppression. 2014 Transpl. Immunol. pmid:24709525
Al-Kadhimi Z et al. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. 2014 Biol. Blood Marrow Transplant. pmid:24709007
Madian AG et al. Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution. 2014 BMC Pharmacol Toxicol pmid:25472557
Indriolo A and Ravelli P Clinical management of inflammatory bowel disease in the organ recipient. 2014 World J. Gastroenterol. pmid:24707135
Veisa G et al. The importance of renal biopsy in the management of renal transplantation. 2014 Apr-Jun Rev Med Chir Soc Med Nat Iasi pmid:25076703
Wang C and Lin A Efficacy of topical calcineurin inhibitors in psoriasis. 2014 Jan-Feb J Cutan Med Surg pmid:24377467
Feito-Rodríguez M et al. Bacterial vaginosis in the context of lichen sclerosus in a prepubertal girl. 2014 Jan-Feb Pediatr Dermatol pmid:24125016
Kabrine M and Laraba-Djebari F Immunomodulatory and protective properties of tacrolimus in experimental scorpion envenomation. 2014 Jan-Mar Int J Immunopathol Pharmacol pmid:24674680
Aktürk S et al. Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. 2015 Transplant. Proc. pmid:26093738
Li DW et al. Risk factors for new onset diabetes mellitus after liver transplantation: A meta-analysis. 2015 World J. Gastroenterol. pmid:26034369
Kawaoka T et al. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. 2015 Transplant. Proc. pmid:25891736
Bruckmueller H et al. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus. 2015 Ther Drug Monit pmid:25271728
Moscovici BK et al. Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study. 2015 Cont Lens Anterior Eye pmid:25956572
Torres-Espín A et al. Immunosuppression of allogenic mesenchymal stem cells transplantation after spinal cord injury improves graft survival and beneficial outcomes. 2015 J. Neurotrauma pmid:25203134
Hur J et al. Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. 2015 Chem. Res. Toxicol. pmid:25811541
Malvezzi P and Rostaing L The safety of calcineurin inhibitors for kidney-transplant patients. 2015 Expert Opin Drug Saf pmid:26329325
Pidala J et al. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. 2015 Haematologica pmid:25840599
Diaz-Siso JR et al. Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. 2015 Am. J. Transplant. pmid:25777324
Lehman N et al. Left subconjunctival hemorrhage · renal dysfunction · international normalized ratio of 4.5 · Dx? 2015 J Fam Pract pmid:26551480
TruneÄŒka P et al. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. 2015 Am. J. Transplant. pmid:25707487
Chen QQ et al. Kaposi's Varicelliform Eruption During Long-term Treatment of Rosacea with 0.03% Tacrolimus Ointment. 2015 Chin. Med. J. pmid:26481759
Shengyou Y et al. Influence of tacrolimus on podocyte injury inducted by angiotensin II. 2015 J Renin Angiotensin Aldosterone Syst pmid:25650384
Yang F et al. A clinicopathological study of renal biopsies from 288 elderly patients: analysis based on 4,185 cases. 2015 Int Urol Nephrol pmid:25539617
Seeling W et al. Knowledge-based immunosuppressive therapy for kidney transplant patients--from theoretical model to clinical integration. 2015 Stud Health Technol Inform pmid:26262418